 Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: The efficacy of niraparib in advanced breast cancer with BRCA1/2 germline mutations

Clin Cancer Res: The efficacy of niraparib in advanced breast cancer with BRCA1/2 germline mutations

 Last Update: 2021-11-02
 Source: Internet
 Author: User

Tags

paw paw cancer

arsenic cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Women with breast cancer with BRCA1/2 germline mutations (gBRCAm) are sensitive to platinum-based chemotherapy and PARP inhibitors, which target potential defects in DNA repair

Breast cancer Niraparib (Niraparib) is an effective oral selective PARP inhibitor that has been proven effective for ovarian cancer and prostate cancer

Recruited HER2-negative advanced breast cancer patients with gBRCAm who had been treated with no more than 2-line chemotherapy and were randomly (2:1) assigned to the niraparib group and the chemotherapy group determined by the doctor (PC; Eribulin, Cappe Monotherapy with tabine, vinorelbine or gemcitabine)

In the interim and final analysis, the PFS assessed by the center

After a pre-planned interim analysis, recruitment was stopped due to ineffectiveness (the PC group’s local and central assessments of PFS were highly inconsistent, leading to information review)

In the final analysis (median follow-up was 19.

OS in both treatment groups

In summary, although there is clear evidence that niraparib has therapeutic activity in the patient population evaluated in this study, the review of information in the control group prevents accurate evaluation of the experimental hypothesis

Original source:

Nicholas C.

Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG / BIG5-13 / TESARO PR-30-50-10-C BRAVO Study

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Clin Cancer Res: The efficacy of niraparib in the treatment of advanced breast cancer with BRCA1/2 germline mutations

09-11

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Clin Cancer Res: The efficacy of niraparib in advanced breast cancer with BRCA1/2 germline mutations

Related Articles

Clin Cancer Res: The efficacy of niraparib in the treatment of advanced breast cancer with BRCA1/2 germline mutations